{"id":33174,"date":"2024-05-10T04:02:53","date_gmt":"2024-05-10T04:02:53","guid":{"rendered":"https:\/\/zydq.1006ss.com\/?p=33174"},"modified":"2024-05-10T04:02:53","modified_gmt":"2024-05-10T04:02:53","slug":"%e5%89%8d%e6%b2%bf%e7%83%ad%e7%82%b9%e4%b8%a8%e7%a5%9d%e8%b4%bapaola-1-os%e7%bb%93%e6%9e%9c%e5%85%a8%e6%96%87%e5%8f%91%e8%a1%a8%e4%ba%8eannals-of-oncology%e6%9d%82%e5%bf%97","status":"publish","type":"post","link":"http:\/\/zydq.1006ss.com\/?p=33174","title":{"rendered":"\u524d\u6cbf\u70ed\u70b9\u4e28\u795d\u8d3aPAOLA-1 OS\u7ed3\u679c\u5168\u6587\u53d1\u8868\u4e8eAnnals of Oncology\u6742\u5fd7"},"content":{"rendered":"

PAOLA-1\u7814\u7a76\u6700\u7ec8OS\u5206\u6790\u7ed3\u679c\u7ee72022\u5e749\u6708\u5728\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09\u5e74\u4f1a\u4e0a\u53e3\u5934\u62a5\u544a\u4e4b\u540e\uff0c2023\u5e745\u670819\u65e5\uff0c\u5176\u5168\u6587\u5728\u56fd\u9645\u80bf\u7624\u5b66\u6743\u5a01\u6742\u5fd7\u300a\u80bf\u7624\u5b66\u5e74\u9274\u300b\uff08Annals of Oncology\uff09\uff08IF=51.769\uff09\u4e0a\u6b63\u5f0f\u5728\u7ebf\u53d1\u8868\uff0c\u663e\u793a\u5965\u62c9\u5e15\u5229\u8054\u5408\u8d1d\u4f10\u73e0\u5355\u6297\u7ef4\u6301\u6cbb\u7597\u5bf9\u4e00\u7ebf\u540c\u6e90\u91cd\u7ec4\u7f3a\u9677\uff08HRD\u9633\u6027\uff09\u7684\u665a\u671f\u5375\u5de2\u764c\u60a3\u8005\u5177\u6709\u957f\u671f\u751f\u5b58\u83b7\u76ca[1]\u3002<\/p>\n<\/p>\n

\u4e00\u3001PAOLA-1\u7814\u7a76\u80cc\u666f<\/p>\n

PAOLA-1\u662f\u4e00\u9879\u968f\u673a\u5bf9\u7167\u3001\u53cc\u76f2\u3001\u2162\u671f\u7814\u7a76\uff0c\u7eb3\u5165806\u4f8b\u63a5\u53d7\u542b\u94c2\u5316\u7597\u8054\u5408\u8d1d\u4f10\u73e0\u5355\u6297\u540e\u8fbe\u7f13\u89e3\u7684\u65b0\u8bca\u65ad\u665a\u671f\u5375\u5de2\u764c\u60a3\u8005\uff0c\u4ee52:1\u6bd4\u4f8b\u968f\u673a\u63a5\u53d7\u5965\u62c9\u5e15\u5229 \u8d1d\u4f10\u73e0\u5355\u6297\u6216\u5b89\u6170\u5242 \u8d1d\u4f10\u73e0\u5355\u6297\u7ef4\u6301\u6cbb\u7597\uff0c\u65e8\u5728\u8bc4\u4f30\u5965\u62c9\u5e15\u5229 \u8d1d\u4f10\u73e0\u5355\u6297\u7ef4\u6301\u6cbb\u7597\u7684\u7597\u6548\u4e0e\u5b89\u5168\u6027\u3002<\/p>\n

\u5728\u65e2\u5f80\u53d1\u5e03\u7684PAOLA-1\u4e3b\u8981\u7ec8\u70b9\u5206\u6790\u4e2d\uff0c\u5965\u62c9\u5e15\u5229 \u8d1d\u4f10\u73e0\u5355\u6297\u5bf9\u6bd4\u8d1d\u4f10\u73e0\u5355\u6297\u663e\u793a\u51fa\u4e86\u8fdb\u4e00\u6b65\u7684\u663e\u8457\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u83b7\u76ca\uff08HR=0.59\uff0cP\uff1c0.001\uff09\uff0c\u5176\u4e2d HRD\u9633\u6027\u60a3\u8005\u83b7\u76ca\u66f4\u52a0\u660e\u663e\uff08HR=0.33\uff09\u3002\u672c\u6b21\u6700\u7ec8\u603b\u751f\u5b58\uff08OS\uff09\u5206\u6790\u5728\u9996\u6b21PFS\u5206\u6790\u540e3\u5e74\u8fdb\u884c\uff0c\u6570\u636e\u6210\u719f\u5ea6\u4e3a55%\uff08\u6570\u636e\u622a\u6b622022\u5e743\u670822\u65e5\uff09\u3002OS\u5206\u6790\u7684\u4e2d\u4f4d\u968f\u8bbf\u65f6\u95f4\u8d85\u8fc761\u4e2a\u6708\uff0c\u62a5\u544a\u4e86\u4e0d\u540c\u57fa\u56e0\u72b6\u6001\u4e9a\u7ec4\u7684OS\u7ed3\u679c\uff0c\u4ee5\u53ca\u66f4\u65b0\u7684HRD\u9633\u6027\u4eba\u7fa4PFS\u7ed3\u679c\u3002<\/p>\n

\u4e8c\u3001PAOLA-1\u7814\u7a76\u8868\u660e\uff1a\u5965\u62c9\u5e15\u5229 \u8d1d\u4f10\u73e0\u5355\u6297\u5bf9HRD\u9633\u6027\u4eba\u7fa4\u6709\u957f\u671f\u751f\u5b58\u83b7\u76ca<\/p>\n

1\u3001\u5965\u62c9\u5e15\u5229 \u8d1d\u4f10\u73e0\u5355\u6297\u7ec4mOS\u9ad8\u8fbe75.2\u4e2a\u6708\uff0c5\u5e74OS\u7387\u9ad8\u8fbe65.5%<\/p>\n

\u5728\u5bf9PARP\u6291\u5236\u5242\u66f4\u52a0\u654f\u611f\u7684HRD\u9633\u6027\u4eba\u7fa4\u4e2d\uff0c\u5c3d\u7ba1\u5bf9\u7167\u7ec4\u4e2d\u670950%\u7684\u60a3\u8005\u5728\u75be\u75c5\u8fdb\u5c55\u540e\u63a5\u53d7\u4e86PARP\u6291\u5236\u5242\uff0c\u4f46\u5965\u62c9\u5e15\u5229 \u8d1d\u4f10\u73e0\u5355\u6297\u7ec4\u7684\u4e2d\u4f4d OS\u8fbe75.2\u4e2a\u6708\uff0c\u8f83\u5bf9\u7167\u7ec457.3\u4e2a\u6708\u5ef6\u957f\u4e86\u8fd118\u4e2a\u6708\uff1b5\u5e74OS\u7387\u9ad8\u8fbe65.5%\uff0c\u8f83\u5b89\u6170\u5242\u7ec4\u63d0\u5347\u4e8617%\uff0c\u6b7b\u4ea1\u98ce\u9669\u964d\u4f4e38%\uff08HR=0.62\uff0c95%CI 0.45~0.85\uff09\uff08\u56fe1\uff09\u3002<\/p>\n

\u56fe1. PAOLA-1\u7814\u7a76\u4e2dHRD\u9633\u6027\u4e9a\u7ec4OS\u3002\u9488\u5bf9BRCA\/HRD\u72b6\u6001\u7684\u4e9a\u7ec4\u5206\u6790\u7ed3\u679c\u663e\u793a\uff0cHRD\u9633\u6027\u4eba\u7fa4\u4e2d\uff0c\u4e0d\u7ba1\u60a3\u8005\u662f\u5426\u6709BRCAm\uff0c\u4e5f\u5747\u89c2\u5bdf\u5230\u6709\u4e34\u5e8a\u610f\u4e49\u7684\u83b7\u76ca\u3002HRD\u9633\u6027\/BRCAm\u60a3\u8005\u63a5\u53d7\u5965\u62c9\u5e15\u5229 \u8d1d\u4f10\u73e0\u5355\u6297\u6539\u5584\u4e86OS\uff0875.2\u4e2a\u6708 vs. 66.9\u4e2a\u6708\uff0cHR=0.60\uff0c95%CI 0.39~0.93\uff09\uff08\u56fe2\uff09\uff1b\u800c\u975eBRCAm\u7684HRD\u9633\u6027\u60a3\u8005OS\u4e5f\u5f97\u5230\u6539\u5584\uff08NR vs. 52\u4e2a\u6708\uff0cHR=0.71\uff0c95%CI 0.45~1.13\uff09\uff08\u56fe3\uff09\u3002<\/p>\n

\u56fe2. PAOLA-1\u7814\u7a76\u4e2dHRD\u9633\u6027\/BRCAm\u60a3\u8005OS\u3002<\/p>\n

\u56fe3. PAOLA-1\u7814\u7a76\u4e2d\u6392\u9664BRCAm\u7684HRD\u9633\u6027\u60a3\u8005OS\u3002<\/p>\n

2\u3001\u5965\u62c9\u5e15\u5229 \u8d1d\u4f10\u73e0\u5355\u6297\u7ec4mPFS\u8fbe46.8\u4e2a\u6708\uff0c5\u5e74PFS\u7387\u8fbe46.1%<\/p>\n

\u968f\u8bbf5\u5e74\u65f6\uff0c\u66f4\u65b0\u7684PFS\u6570\u636e\u663e\u793a\uff0c\u5728HRD\u9633\u6027\u60a3\u8005\u4e2d\uff0c\u5965\u62c9\u5e15\u5229 \u8d1d\u4f10\u73e0\u5355\u6297\u7ec4\u7684\u4e2d\u4f4dPFS\u8f83\u5b89\u6170\u5242\u7ec4\u660e\u663e\u5ef6\u957f\uff0846.8\u4e2a\u6708 vs. 17.6\u4e2a\u6708\uff0cHR=0.41\uff0c95%CI 0.32~0.54\uff09\uff0c5\u5e74\u65f6\u5b58\u6d3b\u4e14\u672a\u8fdb\u5c55\u7684\u60a3\u8005\u6bd4\u4f8b\u4e5f\u660e\u663e\u66f4\u9ad8\uff0846.1% vs. 19.2%\uff09\uff08\u56fe4\uff09\u3002<\/p>\n<\/p>\n

\u56fe4. PAOLA-1\u7814\u7a76\u4e2dHRD\u9633\u6027\u60a3\u8005PFS\u3002<\/p>\n

3\u3001\u8054\u5408\u7528\u836f\u65b9\u6848\u7684\u5b89\u5168\u6027\u4e0e\u8d1d\u4f10\u73e0\u5355\u6297\u5355\u836f\u6cbb\u7597\u57fa\u672c\u4e00\u81f4<\/p>\n

\u81f3\u4e8e\u6cbb\u7597\u5b89\u5168\u6027\u95ee\u9898\uff0cPAOLA-1\u7814\u7a76\u5728\u4e2d\u4f4d\u8d85\u8fc75\u5e74\u7684\u968f\u8bbf\u8fc7\u7a0b\u4e2d\uff0c\u672a\u89c2\u5bdf\u5230\u65b0\u7684\u5b89\u5168\u6027\u4fe1\u53f7\uff0c\u4e24\u7ec4\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\uff08MDS\uff09\u3001\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u3001\u518d\u751f\u969c\u788d\u6027\u8d2b\u8840\uff08AA\uff09\u7684\u53d1\u751f\u7387\u5747\u57282%\u5de6\u53f3\uff0c\u65b0\u53d1\u6076\u6027\u80bf\u7624\u7684\u6bd4\u4f8b\u5728\u4e24\u7ec4\u4e2d\u4ea6\u4fdd\u6301\u5747\u8861\uff0c\u8054\u5408\u7528\u836f\u65b9\u6848\u7684\u6574\u4f53\u5b89\u5168\u6027\u53ef\u63a7\uff0c\u4e0e\u65e2\u5f80\u7814\u7a76\u7ed3\u679c\u57fa\u672c\u4fdd\u6301\u4e00\u81f4\u3002<\/p>\n

\u4e09\u3001\u4e34\u5e8a\u610f\u4e49\uff1aPAOLA-1\u7814\u7a76\u9996\u6b21\u8bc1\u660e\u4e00\u7ebfPARP\u6291\u5236\u5242\u65b9\u6848\u5bf9HRD\u9633\u6027\u4eba\u7fa4\u5e26\u6765\u957f\u671f\u751f\u5b58\u83b7\u76caPARP\u6291\u5236\u5242\u4f5c\u4e3a\u665a\u671f\u5375\u5de2\u764c\u60a3\u8005\u4e00\u7ebf\u7ef4\u6301\u6cbb\u7597\u836f\u7269\u5b8c\u6210\u4e86\u591a\u9879 III\u671f\u4e34\u5e8a\u968f\u673a\u5bf9\u7167\u8bd5\u9a8c[2-8]\uff08\u88681\uff09\u3002\u57fa\u4e8e\u73b0\u6709\u4e34\u5e8a\u7814\u7a76\u8bc1\u636e\uff0c\u56fd\u5185\u5916\u6307\u5357\u4e00\u81f4\u63a8\u8350PARP\u6291\u5236\u5242\u3001\u6297\u8840\u7ba1\u751f\u6210\u836f\u7269\u3001PARP\u6291\u5236\u5242 \u6297\u8840\u7ba1\u751f\u6210\u836f\u7269\u8054\u5408\u65b9\u6848\u7528\u4e8e\u5375\u5de2\u764c\u60a3\u8005\u7684\u7ef4\u6301\u6cbb\u7597\u3002\u76ee\u524d\u6211\u56fd\u83b7\u6279\u7528\u4e8e\u5375\u5de2\u764c\u60a3\u8005\u4e00\u7ebf\u7ef4\u6301\u6cbb\u7597\u7684\u65b9\u6848\u6709\u5965\u62c9\u5e15\u5229\u3001\u5c3c\u62c9\u5e15\u5229\uff0c\u4ee5\u53ca\u5965\u62c9\u5e15\u5229 \u8d1d\u4f10\u73e0\u5355\u6297[9]\u3002<\/p>\n

\u8868 1. PARP\u6291\u5236\u5242\u4e00\u7ebf\u7ef4\u6301\u6cbb\u7597\u7684\u7597\u6548\u6570\u636e\u6c47\u603b<\/p>\n

\u6ce8\u610f\uff1a\u975e\u5934\u5bf9\u5934\u7814\u7a76\uff0c\u4e0d\u80fd\u76f4\u63a5\u6bd4\u8f83\u3002<\/p>\n

\u665a\u671f\u5375\u5de2\u764c\u60a3\u8005\u91c7\u7528\u4f20\u7edf\u6cbb\u7597\u65b9\u6cd5\u76845\u5e74\u751f\u5b58\u7387\u4ec5\u7ea630%\uff0cPARP\u6291\u5236\u5242\u7684\u51fa\u73b0\u53ca\u5176\u5728\u5375\u5de2\u764c\u4e00\u7ebf\u6cbb\u7597\u65b9\u6848\u4e2d\u7684\u5e94\u7528\uff0c\u4e3a\u63a8\u8fdf\u80bf\u7624\u590d\u53d1\u3001\u5ef6\u957f\u60a3\u8005\u751f\u5b58\u5e76\u63d0\u5347\u6cbb\u6108\u53ef\u80fd\u5e26\u6765\u4e86\u65b0\u7684\u66d9\u5149\u3002\u672c\u6b21PAOLA-1\u6700\u7ec8OS\u7ed3\u679c\u6b63\u5f0f\u53d1\u8868\uff0c\u8fd9\u662f\u7b2c\u4e00\u6b21\u6709PARP\u6291\u5236\u5242\u7814\u7a76\u663e\u793a\u5176\u5bf9HRD\u9633\u6027\u7684\u65b0\u8bca\u65ad\u665a\u671f\u5375\u5de2\u764c\u60a3\u8005\u5177\u6709\u4e34\u5e8a\u610f\u4e49\u7684OS\u83b7\u76ca\uff0c\u800c\u4e14\u4e0d\u7ba1BRCA\u7a81\u53d8\u60c5\u51b5\u5982\u4f55\uff0cOS\u5747\u660e\u663e\u5ef6\u957f\u3002\u5bf9\u4e8e\u5360\u5230\u665a\u671f\u5375\u5de2\u764c\u75c5\u4f8b\u4e00\u534a\u7684HRD\u9633\u6027\u60a3\u8005\uff0c\u91c7\u7528\u5965\u62c9\u5e15\u5229 \u8d1d\u4f10\u73e0\u5355\u6297\u4f5c\u4e3a\u4e00\u7ebf\u7ef4\u6301\u6cbb\u7597\uff0c\u57282\u5e74\u7ef4\u6301\u6cbb\u7597\u7528\u836f\u4e4b\u540e\u53ef\u4ee5\u6301\u7eed\u4e3a\u60a3\u8005\u5e26\u6765\u5177\u6709\u4e34\u5e8a\u610f\u4e49\u7684\u603b\u751f\u5b58\u83b7\u76ca\uff0c\u60a3\u8005\u5728\u957f\u671f\u968f\u8bbf\u4e2d\u4ecd\u7136\u4fdd\u6301\u5f88\u9ad8\u7684\u751f\u5b58\u7387\uff0c\u771f\u6b63\u5e2e\u52a9\u60a3\u8005\u8fdb\u5165\u6162\u75c5\u7ba1\u7406\u9636\u6bb5\u3002<\/p>\n

\u53c2\u8003\u6587\u732e(\u5411\u4e0a\u2191\u6ed1\u52a8\u67e5\u770b\u5168\u90e8\uff09<\/p>\n

1. Ray-Coquard, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Annals of Oncology May 19, 2023. DOI: https:\/\/\/10.1016\/j.annonc.2023.05.005.  <\/p>\n

2. Banerjee S, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021; 22(12): 1721-1731.   <\/p>\n

3. DiSilvestro P, et al. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1\/GOG 3004 Trial. J Clin Oncol. 2022; JCO 2201549.   <\/p>\n

4. Ray-Coquard I, et al. Final overall survival (OS) results from the phase III PAOLA-1\/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). 2022 ESMO abstr LBA29.   <\/p>\n

5. Gonz\u00e1lez-Mart\u00edn A, et al. PRIMA\/ENGOT-OV26\/GOG-3012 study: Updated long-term PFS and safety. 2021 ESMO abstr 530P.   <\/p>\n

6. Gonz\u00e1lez-Mart\u00edn A, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019; 381(25): 2391-2402.   <\/p>\n

7. Li N, et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): a randomized, double-blind, placebo-controlled, phase 3 trial. 2022 SGO Annual Meeting on Women\u2019s Cancer.   <\/p>\n

8. Monk BJ, et al. ATHENA\u2013MONO (GOG-3020\/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer. 2022 ASCO abstr LBA5500.   <\/p>\n

9. \u4e2d\u56fd\u5375\u5de2\u4e0a\u76ae\u6027\u764c\u7ef4\u6301\u6cbb\u7597\u6307\u5357\uff082022 \u5e74\u7248\uff09[J]. \u4e2d\u56fd\u5b9e\u7528\u5987\u79d1\u4e0e\u4ea7\u79d1\u6742\u5fd7,2022, 38(01): 56-65.<\/p>\n

\u58f0\u660e\uff1a\u672c\u6750\u6599\u7531\u963f\u65af\u5229\u5eb7\u63d0\u4f9b\uff0c\u4ec5\u4f9b\u533b\u7597\u536b\u751f\u4e13\u4e1a\u4eba\u58eb\u53c2\u8003\u3002\u5ba1\u6279\u7f16\u53f7\uff1aCN-116205\uff1b\u6709\u6548\u671f\uff1a2023\u5e7412\u670831\u65e5\u3002\u672c\u6587\u4ec5\u4f9b\u533b\u7597\u536b\u751f\u4e13\u4e1a\u4eba\u58eb\u4e3a\u4e86\u89e3\u8d44\u8baf\u4f7f\u7528\uff0c\u4e0d\u4ee3\u8868\u672c\u5e73\u53f0\u89c2\u70b9\u3002\u8be5\u7b49\u4fe1\u606f\u4e0d\u80fd\u4ee5\u4efb\u4f55\u65b9\u5f0f\u53d6\u4ee3\u4e13\u4e1a\u7684\u533b\u7597\u6307\u5bfc\uff0c\u4e5f\u4e0d\u5e94\u88ab\u89c6\u4e3a\u8bca\u7597\u5efa\u8bae\u3002\u5982\u8be5\u7b49\u4fe1\u606f\u88ab\u7528\u4e8e\u4e86\u89e3\u8d44\u8baf\u4ee5\u5916\u7684\u76ee\u7684\uff0c\u5e73\u53f0\u53ca\u4f5c\u8005\u4e0d\u627f\u62c5\u76f8\u5173\u8d23\u4efb\u3002<\/p>\n

#artContent h1#artContent p img#artContent table<\/p>\n","protected":false},"excerpt":{"rendered":"

PAOLA-1\u7814\u7a76\u6700\u7ec8OS\u5206\u6790\u7ed3\u679c\u7ee72022\u5e749\u6708\u5728\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09 … \u7ee7\u7eed\u9605\u8bfb →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[70],"tags":[],"class_list":["post-33174","post","type-post","status-publish","format-standard","hentry","category-70"],"_links":{"self":[{"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=\/wp\/v2\/posts\/33174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33174"}],"version-history":[{"count":0,"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=\/wp\/v2\/posts\/33174\/revisions"}],"wp:attachment":[{"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33174"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/zydq.1006ss.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}